CURRICULUM VITAE

Name: Wyndham Hopkins Wilson

Citizenship: United States

Place of Birth: San Francisco, California

Home Address: 3101 Rittenhouse St., N.W.

> Washington, D.C. 20015
>
> 202-966-7621

Work Address: Building 10, Room 4N-115

> National Cancer Institute
>
> 9000 Rockville Pike
>
> Bethesda, Maryland 20892

301-435-2415

Fax: 301-480-4087

Current Position: Principal Investigator and

Chief, Lymphoma Therapeutics Section

Metabolism Branch

> Center for Cancer Research
>
> National Cancer Institute

# Education 

1970-1974 B.A. (Human Biology)

> Stanford University, Stanford, CA

1974-1975 M.S. (Biology)

> Stanford University, Stanford, CA

1975-1981 Ph.D. (Neurobiology)

> Stanford University, Stanford, CA

M.D. (Stanford School of Medici­ne)

> Stanford Univer­sity, Stan­ford, CA

# Positions 

1976-1977 Teaching Assistant, Department of Neurobiology,

Stanford University, Stanford, CA

1978 Acting Assistant Instructor, Department of Neuro­biology, Stanford
Univer­sity, Stan­ford, CA

1979-1980 Teaching Assistant, Department of Neurobiology, Stanford

Univer­sity, Stan­ford, CA

1981-1982 Internship, Department of Medicine,

> Stanford Univer­sity, Stan­ford, CA

1982-1984 Junior and Senior Resident, Department of Medicine, Stanford
Univer­sity, Stanford, CA

1984-1987 Medical Staff Fellow, Medicine Branch, National Cancer
In­stitute, NIH, Bethes­da, MD

1985-1994 Emergency Department Physician, City Hospital, Martinsburg,
West Virginia (Part-time).

1987-1988 Medical Staff Fellow, Pediatric Branch, Infectious Disease
Section, National Cancer Institute, NIH, Bethesda, MD

1988-1995 Special Assistant to the Director, Division of Cancer
Treatment, National Cancer Institute, NIH, Bethesda, MD

1995-2002 Senior Investigator, Medicine Branch, Division of Clinical

> Sciences, National Cancer Institute, NIH, Bethesda, MD

1997-Present Chief, Lymphoma Clinic, Medicine Branch, Division of
Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD

1998. Oncology Fellowship Coordinator, Medicine Branch, Division of
      Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD

1998-1999 Chief, Clinical Core, Metabolism Branch, Division of Clinical
Sciences, National Cancer Institute, NIH, Bethesda, MD

2002-2005 Senior Investigator, Chief, Lymphoma Section, Experimental
Transplantation and Immunology Branch, National Cancer Institute, NIH,
Bethesda, MD.

2005-Present Senior Investigator, Chief, Lymphoma Therapeutics Section,
Metabolism Branch, Center for Cancer Research, National Cancer
Institute, NIH, Bethesda, MD

# Licensed to Practice Medicine

West Virginia License \# 14230

# Certification

1982 Diplomat, National Board of Medical Examiners

1985 Diplomat, American Board of Internal Medicine

1987 Diplomat, Subspecialty of Oncology, American Board of Internal
Medicine

**Society Membership**

1990-Present American Society of Oncology

1996-Present American Society of Hematology

# Committees at NIH

1988-1989 Chairman, Fluoro-dideoxyinosine and Fluoro-dideoxycytidine
Licensing Committee, DCT, NCI

1988-1995 Chairman, Animal Care and Use Committee, DCT, NCI

1992-1993 Member, Natural Products Repository Review Committee

1992-1995 Member, Institutional Review Board, NCI

1995-Present Member, Protocol Review and Monitoring Committee, DCS, NCI

1995-2002 Chairman, Institutional Review Board, NCI

1999-2001 Member, Promotions and Tenure Review Committee, DCS, NCI

2001-Present Chairman, Promotions and Tenure Review Committee for
Clinical Staff, CCR, NCI

# Academic Honors

1974 B.A. with Honors in Human Biology

1976-1981 Medical Scientist Training Program Grant Award

1994 Merit Award, National Institutes of Health

1997. Teacher of the Year Award, Medicine Branch and Division of
      Clinical Sciences, National Cancer Institute

1998. Director's Award, National Institutes of Health

2000 Director's Award, Division of Clinical Sciences, NCI

# Editorial Boards

1994-Present *Physicians Data Query (PDQ) External Advisory Board*

1999-Present *Clinical Lymphoma*

2000-2003 *Journal of Clinical Oncology*

2002-Present *The Oncologist*

2006-Present *Leukemia and Lymphoma, Associate Editor*

# Invited Reviewer 

## Journal of Clinical Oncology

Blood

American Journal of Hematology

Clinical Cancer Research

Cancer Research

European Journal of Hematology

Journal of National Cancer Institute

Oncology

Oncologist

Clinical Investigation

Clinical Lymphoma

Acta Haematologica

International Journal of Cancer

Journal of Immunotherapy

New England Journal of Medicine

Lancet Oncology

Annals of Oncology

Leukemia and Lymphoma

### Extramural Activities

2000-Present Member, CALGB Cooperative Group

2000-Present Executive Director, Progress Review Group for Lymphoma,
Leukemia and Multiple Myeloma

2001 Member, Planning Committee, American Society of Hematology Meeting,
2001

2002-Present Scientific Advisory Board, International Working Group on
non-Hodgkin's Lymphoma (IwNHL)

2005-Present Committee on Neoplasia, American Society of Hematology

# Patents and Licenses

1.  Wilson WH and Wittes R: Taxol treatment of breast cancer. *United
    States Patent* 5,496,846, 1996.

2.  Wilson W, Reed E, Vande Woude , et al. Bristol-Myers Squibb Company
    for Taxol® . NIH License Agreement L-277-96/0, 1996.

3.  Staudt LM, Barry TS, Rosenwald A, Wiestner A, Wilson W: ZAP-70
    Protein Expression as a Marker for Chronic Lymphocytic
    Leukemia/Small Lymphocytic Leukemia (CLL/SLL). (Patent Submitted).

4.  Kreitman R, Matsushita, K, Wilson W, Pastan I: ELISA Assay of Serum
    Soluble CD22 to Assess Tumor Burden/Relapse in Patients with B-cell
    Leukemia and Lymphoma. (Patent Submitted).

# Bibliography

1\. Wilson WH and Heller HC: Elevated blood glucose levels and satiety
in the rat. *Physiol Behav* 15:137-143, 1975.

2\. Burton LE, Wilson WH and Shooter EM: Nerve Growth Factor in mouse
saliva; Rapid isolation procedures for and characterization of 7 S Nerve
Growth Factor. *J Biol Chem* 253:7807-7812, 1978.

3\. Wilson WH and Shooter EM: Structural modification of the
NH2-terminus of Nerve Growth Factor; Purification and characterization
of Beta-Nerve Growth Factor endopeptidase. *J Biol Chem* 254:6002-6009,
1979.

4\. Bothwell MA, Wilson WH and Shooter EM: The relationship between
glandular kallikrein and growth factor-processing proteases of mouse
submaxillary gland. *J Biol Chem* 254:7287-7294, 1979.

5\. Jacobs MB and Wilson W: Iron deficiency anemia in a vegetarian
runner. *JAMA* 252(4):481-482, 1984.

6\. Lane CH, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur
H, Leitman SF, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone
marrow transplantation and adoptive transfer of peripheral blood
lymphocytes combined with Zidovudine in human immunodeficiency virus
infection. *Ann Intern Med* 113:512-519, 1990.

7\. Wilson WH, Magrath I: Principles of chemotherapy. In The
Non-Hodgkin\'s Lym­phomas. I. Magrath, editor, Edward Arnold, publisher,
London, 1990.

8\. Longo DL, Wilson WH: Follicular lymphomas. In The Non-Hodgkin\'s
Lymphomas. I. Magrath, editor, Edward Arnold, publisher, London, 1990.

9\. Barriga F, Magrath I, Wilson WH: Complications in the management of
non-Hodgkin\'s lymphomas. In The Non-Hodgkin\'s Lymphomas. I. Magrath,
editor, Edward Arnold, publisher, London, 1990.

10\. Magrath I, Wilson WH, Horgath M, Neumann R, Barriga F: Clinical
features and staging. In The Non-Hodgkin\'s Lymphomas. I. Magrath,
editor, Edward Arnold, publisher, London, 1990.

11\. Rothenberg M, Wilson W, Chabner BA: Complications of drug therapy
for cancer: General review. In The Complications of Cancer Management.
Plowman, P.N., McElwain, T.J., and Meadows A.T., editors,
Butterworth-Heinemann, publishers, U.K., 1991.

12\. Chabner BA, Wilson WH: Reversal of multidrug resistance.
\[Editorial\] *J Clin Oncol* 9:4-6, 1991.

13\. Burt RK, Sharfman WH, Karp BI and Wilson WH: Mental neuropathy, a
harbinger of tumor progression or relapse. *Cancer* 70:877-881, 1992.

14\. Urba WJ, Wilson WH, Duffey PL, Wittes R, Chabner BA and Longo DL:
Recent NCI lymphoma trials of etoposide-containing combination
chemotherapy. *Semin in Oncol* 19:26-32, 1992.

15\. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M,
Goldspiel B, Steinberg SM, Longo DL, Wittes RE: Phase I-II Study of
high-dose ifosfamide, carboplatin and etoposide (ICE) with autologous
bone marrow rescue in lymphomas and solid tumors. *J Clin Oncol*
10:1712-1722, 1992.

16\. Bergan R and Wilson WH: Pulmonary toxicity of cancer therapy.
*Intern Med* 13:56-65, 1992.

17\. Quezado ZMN, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G,
Ognibene FP: High-dose ifosfamide is associated with severe, reversible
cardiac dysfunction. *Ann Intern Med* 118:31-36, 1993.

18\. Wilson WH: High-dose chemotherapy and autologous transplantation
with peripheral blood stem cells by Vose J, Armitage J, Kessinger A.
\[Commentary\] *Oncology* 7:33-34, 1993.

19\. Goldspiel BR, Kohler DR, Koustenis AG, Wilson WH, Tolcher AW,
OShaughnessy JA, Wittes RE, Chabner BA: Paclitaxel administration using
portable infusion pumps. \[Letter\] *J Clin Oncol* 11:2287-2288, 1993.

20\. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM,
Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA. EPOCH Chemotherapy:
Toxicity and efficacy in relapsed and refractory non-Hodgkin\'s
lymphoma. *J Clin Oncol* 11:1573-1582, 1993.

21\. O\'Shaughnessy JA, Cowan KH, Wilson W, Bryant G, Goldspiel B, Gress
R, Nienhuis AW, Dunbar C, Sorrentino B, Stewart FM, Moen R, Fox M,
Leitman S: Clinical Protocol-Pilot study of high dose ICE (ifosfamide,
carboplatin, etoposide) chemotherapy and autologous bone marrow
transplant with *neo*^R^-transduced bone marrow and peripheral blood
stem cells in patients with metastatic breast cancer. *Human Gene
Therapy* 4:331-354, 1993.

22\. Walsh TJ, Renshaw G, Andrews J, Kwon-Chung J, Cunnion RC, Pass HI,
Taubengerger J, Wilson W and Pizzo PA: Invasive Zygomycosis due to
Conidiobolus incongruus. *Clin Infect Dis* 19:423-430, 1994.

23\. Wilson WH: The role of GM-CSF and G-CSF in stem cell
transplantation by Nemunaitis J. \[Commentary\] *Oncology* 8:17-18,
1994.

24\. Chabner BA, Bates SE, Fojo AT, Spolyar M and Wilson WH: Drug
resistance in adult lymphomas. *Semin in Oncol* 31:70-87, 1994.

25\. O\'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino
BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox M,
Leitman S, Gottesman M, Pastan I, Denicoff A, Noone M, Gress R: Clinical
Protocol-Retroviral mediated transfer of the human multidrug resistance
gene (mdr-1) into hematopoietic stem cells during autologous
transplantation after intensive chemotherapy for metastatic breast
cancer. *Human Gene Therapy* 5:891-911, 1994.

26\. Shilyansky J, Wilson W, Temeck BK and Pass HI: Pulmonary
artery-bronchial fistula during lymphoma treatment. \[Letter\] *J
Thoracic and Cardiovascular Surgery,* 108:790-791, 1994.

27\. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg
SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA:
Paclitaxel in doxorubicin or mitoxantrone refractory breast cancer: A
phase I/II trial of 96-hour infusion. *J Clin Oncol* 12:1621-1629, 1994.

28\. Humphrey RW, Wilson WH: Treatment of non-Hodgkin\'s lymphoma by
Armitage JO. \[Commentary\] *Abst Clin Care Guidelines* 6:4-5, 1994.

29\. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe
ES, Steinberg SM, Goldspiel BR, Cheson BD, Wittes RE: A phase II study
of paclitaxel in relapsed non-Hodgkin\'s lymphomas. *J Clin Oncol*
13:381-386, 1995.

30\. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstein B, Lee JS,
Stetler-Stevenson MA, Jaffe E, Solomon D, Wilson WH, Chabner BA, Fojo A
and Bates SE: Expression of mdr-1 in refractory lymphoma: Quantitation
by PCR and validation of the assay. *Blood* 86:1515-1524, 1995.

31\. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE,
Chabner BA, Steinberg SM, Kohler DR, Wittes RE: Phase I and
pharmacokinetic study of the multidrug resistance modulator dexverapamil
with EPOCH chemotherapy. *J Clin Oncol* 13:1985-1994, 1995.

32\. Wilson WH, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES,
Steinberg SM, Herdt J, Chabner BA: A controlled trial of dexverapamil, a
modulator of multidrug resistance, in lymphomas refractory to EPOCH
chemotherapy. *J Clin Oncol* 13:1995-2004, 1995.

33\. Saville MW, Jietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH,
Humphrey R, Feigal E, Steinberg SM, Broder S and Yarchoan R: Treatment
of HIV-associated Kaposi's Sarcoma with paclitaxel. *Lancet* 346:26-28,
1995.

34\. Chabner BA, Wilson WH: Pharmacology and toxicity of antineoplastic
drugs. In Williams Hematology, Beutler E., Lichtman M.A., Coller B.S.,
and Kipps T.J., editors, McGraw-Hill, Inc publishers USA, 1995.

35\. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C,
Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF,
Wilson WH, Cowan K, Young NS and Nienhuis AW: Retrovirally-marked CD-34
enriched peripheral blood and bone marrow cells contribute to long-term
engraftment after autologous transplantation. *Blood* 85:3048-3957,
1995.

36\. Cheson BD, Wilson WH: Paclitaxel in the treatment of hematological
malignancies. In Paclitaxel in Cancer Treatment. McGurie, W.P. and
Rowinsky, E.K., Editors, Marcel Dekkar Inc, Publisher, New York, 1995.

37. Wilson WH: Drug resistance in non-Hodgkin's lymphomas. *Lymphoma
    Biology and*

*Research* 1:4-5, 1995.

38\. Wilson WH, Bates SE, Fojo A, Chabner BA: Modulation of multidrug
resistance by dexverapamil in EPOCH-refractory lymphomas. *J Can Res
Clin Oncol* 121 (Suppl 3):25-29, 1995.

38. Wilson WH, Kingma DW, Wittes RE, Greiner TC and Jaffe ES:
    Association of Lymphomatoid granulomatosis with Epstein-Barr Viral
    infection of B Lymphocytes and response to alfa-interferon. *Blood*
    87:4531-4537, 1996.

39. Burt RK, Wilson WH: Conditioning regimens. In House Officers Manual
    of Bone Marrow Transplantation. Barrett AJ, Blume KG, et al editors,
    R.G. Landes Company, publisher, 1996.

40. Prussick R, Horn TD, Wilson WH and Turner MC: A cutaneous eruption
    associated with ifosfamide, carboplatin and etoposide chemotherapy
    after recombinant interleukin-1α pretreatment. *J Amer Acad Derm,*
    35:705-709, 1996.

41. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R,
    Hose C, Monks A, Kang YK, Chabner B: Clinical reversal of multidrug
    resistance. *Oncologist*, 1:269-275, 1996.

42. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe
    ES, Raffeld M: Relationship of p53, bcl-2 and MIB-1 proliferative
    antigen to clinical drug resistance in non-Hodgkin's lymphoma.
    *Blood*, 89:601-609, 1997.

43. Georgiadis MS, Schuler BS, Brown JE, Kieffer LV, Steinberg SM,
    Wilson WH, Takimoto CH, Kelley MJ, Johnson BE: Paclitaxel by 96-hour
    continuous infusion in combination with cisplatin: A phase I trial
    in patients with advanced lung cancer. *J Clin Oncol* 15:735-743,
    1997.

44. Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson WH, Fojo
    AT, Bates SE: Expression of the multidrug resistance-associated
    protein gene in refractory lymphoma: Quantitation by a validated
    polymerase chain reaction assay. *Blood* 89:3795-3800, 1997.

45. Wilson WH, Chabner BA: Principles of therapy. In The Lymphomas. G.
    Canellos, T.A. Lister, J.L. Sklar, editors, W.B. Saunders,
    Publisher, 1997.

46. Segal BH, Engler HD, Little R, Wilson WH, Freifeld AG, Chanock SJ:
    Early forscarnt failure in herpes simplex virus infection in a
    patient with AIDS. *AIDS* 11:552-553, 1997.

47. Molldrem J, Wilson WH: Infusional chemotherapy for non-Hodgkin's
    lymphoma. *Cancer Invest* 15:465-474, 1997.

48. Wilson WH: The role of dose intensity in the treatment of
    HIV-associated lymphomas. *N Engl J Med* \[letter\] 337:1172-1173,
    1997.

49. Wilson WH: Principles of chemotherapy. In The Non-Hodgki­n\'s
    Lym­phomas. (Second Edition), I. Magrath, editor, Edward Arnold,
    Publisher, London, 1997.

50. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson
    WH, Longo DL, Tosato G: The role of Mig, the monokine induced by
    interferon-γ, and IP-10, the interferon-γ inducible protein 10, in
    tissue necrosis and vascular damage associated with Epstein-Barr
    virus-positive lymphoproliferative disease. *Blood* 15:4099-4105,
    1997.

51. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Wilson WH,
    Wittes RE, Jaffe ES, Hubbard SM, DeVita Jr. VT: Alternating MOPP and
    ABVD plus mantle field radiation therapy in patients with massive
    mediastinal Hodgkin's disease. *J Clin Oncol* 15:3338-3346, 1997.

52. Sandor V, Wilson W, Fojo A, Bates SE: The role of MDR-1 in
    refractory lymphoma. *Leuk Lymph* 28:23-31, 1997.

53. Jaffe ES, Wilson WH: Lymphomatoid granulomatosis: Pathogenesis,
    pathology and clinical implications. *Cancer Surv* 30:233-248, 1997.

54. Wilson WH: Pharmacokinetics of chemotherapy agents by continuous
    infusion: The Paclitaxel Module. In Infusion Chemotherapy-Radiation
    Interaction: Its Biology and Significance for Organ Salvage and
    Prevention of Second Primary Neoplasms. C. Julian Rosenthal and
    Marvin Rotman, editors, Elsevier, Publisher, Amsterdam, 1998.

55. Mickley LA, Lee JS, Weng Z, Alvarez M, Wilson W, Bates SE, Fojo AT:
    Genetic polymorphism in MDR-1: A tool for examining allelic
    expression in normal cells, unselected and drug-selected cell lines,
    and human tumors. *Blood* 91:1749-1756, 1998.

56. Little R, Wittes RE, Longo DL, Wilson WH: Vinblastine in recurrent
    Hodgkin's disease following autologous stem cell transplant. *J Clin
    Oncol* 16:584-588, 1998.

57. Weng DE, Wilson WH, Little RL, Walsh TJ: Successful medical
    management of isolated renal Zygomycosis: A case report and
    literature review. *Clin Infect Dis* 26:601-605, 1998.

58. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill K, Feuerstein I,
    Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal
    E, Steinberg SM, Broder S, Yarchoan R: Phase II trial with dose
    tiration of paclitaxel for the therapy of Human Immunodeficiency
    Virus-associated Kaposi's sarcoma. *J Clin Oncol* 16:1112-1121,
    1998.

59. Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, Nieder M,
    Owen W, Seibel N, Wilson W, Horak ID, Magrath I: Additional
    chemotherapy agents improve treatment outcome for children and
    adults with advanced B-cell lymphomas. *Semin Oncology* 25 (Suppl
    4):33-39; discussion 45-48, 1998.

```{=html}
<!-- -->
```
60. Wilson WH, Little R, Pearson D, Jaffe E, Steinberg S, Cheson BD,
    Humphrey R, Kohler D, Elwood P. A phase II and dose escalation 
    G-CSF study of 9-aminocamptothecin in relapsed and refractory
    lymphomas. *J Clin Oncol* 16:2345-2351, 1998.

```{=html}
<!-- -->
```
61. Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A,
    Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A,
    Buell D, Barret J and Wilson W: Safety, tolerance and
    pharmacokinetics of a small unilamellar liposomal formulation of
    Amphotericin B (AmBisome) in neutropenic patients. *Antimicrob
    Agents Chemother* 42:2391-2398, 1998.

62. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC:
    Central nervous system involvement in primary mediastinal large
    B-cell lymphoma. *J Clin Oncol* 17:2479-2485, 1999.

63. Kreitman RJ, Wilson WH, Robbines D, Margulies I, Stetler-Stevenson
    MA, Waldman TA, Pastan I: Responses in refractory Hairy Cell
    leukemia to a recombinant immunotoxin. *Blood* 94:3340-3348, 1999.

64. Cowan KH, Moscow JA, Huang H, Zujewski J, O'Shaughnessy J,
    Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M,
    Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF,
    McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM,
    Pastan I, Nienhuis: Paclitaxel chemotherapy following autologous
    stem cell transplantation and engraftment of hematopoietic cells
    transduced with retrovirus containing the multidrug resistance cDNA
    (MDR1) in metastatic breast cancer patients. *Clin Cancer Res*
    5:1619-1628, 1999.

65. Wilson W: Clinical aspects and treatment in angioimmunoblastic T
    cell lymphoma (AILD). In Clinical Implications of the R.E.A.L
    Classification. Mason DY and Harris NL, editors. Springer-Verlag,
    London, Publishers, 1999.

66. Wilson W: Clinical aspects and treatment options in nasal/nasal type
    lymphoma (angiocentric lymphomas) and lymphomatoid granulomatosis.
    In Clinical Implications of the R.E.A.L Classification. Mason DY and
    Harris NL, editors. Springer-Verlag, London, Publishers, 1999.

67. Baris D, Kwak L, Rothman N, Wilson W, Manns A, Tarone RE, Hartge P:
    Blood levels of organochlorines before and after chemotherapy among
    non-Hodgkin's lymphoma patients. *Cancer Epidemiol Biomarkers and
    Prev* 9:193-197, 2000.

68. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson MA, Jaffe E,
    Giardina S, Waldmann TA, Pastan I: Phase I trial of recombinant
    immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic
    malignancies. *J Clin Oncol* 18:1622-1636, 2000.

69. Wilson WH, Sorbara L, Figg WD, Month EK, Sausville E, Warren KE,
    Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A: Modulation of
    clinical drug resistance in a B-cell lymphoma patients by the
    protein kinase inhibitor 7-Hydroxystaurosporine (UCN-01):
    Presentation of a novel therapeutic paradigm. *Clin Cancer Res*
    6:415-421, 2000.

70. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A,
    Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE,
    Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan
    WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R,
    Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM:
    Distinct types of diffuse large B-cell lymphoma by gene expression
    profiling. *Nature* 403:503-511, 2000.

71. Little R, Gutierrez M, Wilson WH: Chemotherapy sensitization by
    rituximab: Presentation of two case studies*. Case Studies in
    Oncology* 2:1-7, 2000.

72. Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause GL, Janik
    JE, Bramen VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler
    LM, Urba WJ: Combination chemotherapy followed by a recombinant
    immunotoxin (anti-B4-blocked ricin) in patients with indolent
    lymphomas: Results of a phase II study. *Cancer J Sci Am* 6:146-150,
    2000.

73. Bishop PC, Rao VK, Wilson W: Burkitt's lymphoma: Molecular
    pathogenesis and treatment. *Cancer Invest* 18:574-583, 2000.

74. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson
    BD, Fojo A, Wilson WH: The role of retreatment with a
    doxorubicin-containing regimen in relapsed and resistant lymphomas:
    An 8 year follow-up study of EPOCH. *J Clin Oncol* 18:3633-3642,
    2000.

75. Little RF, Yarchoan R, Wilson WH: Systemic chemotherapy for
    HIV-associated lymphoma in the era of highly active antiretroviral
    therapy. *Curr Opin Oncol* 12:438-444, 2000.

76. Chabner BA, Wilson W, Supko J: Pharmacology and toxicity of
    antineoplastic drugs. In William's Hematology, 2001.

77. Wilson WH: Chemotherapy sensitization by rituximab: Experimental and
    clinical evidence. *Semin Oncol* 27:30-36, 2001.

78. Gutierrez ME, Grossbard M, Jaffe E, Chabner BA, Wilson WH:
    Dose-adjusted EPOCH-Rituximab (EPOCH-R): An effective regimen in
    poor prognosis aggressive B-cell lymphoma. *Biologic Therapy of
    Lymphoma* 4:10-13, 2001.

79. Saif MW, Little RF, Hamilton M, Allegra CJ and Wilson WH:
    Reactivation of chronic hepatitis B infection following intensive
    chemotherapy and successful treatment with lamivudine: A care report
    and review of the literature. *Ann Oncol* 12:123-129, 2001.

80. Hegde U, Wilson WH: Gene expression profiling of lymphomas. *Curr
    Oncol Reports* 3:243-249, 2001.

81. Jaffe ES, Wilson WH: Lymphomatoid Granulomatosis. Tumours of
    Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours,
    pg 185-187, 2001.

82. Leach FS, Gutierrez M, Pavlovich C, Wilson W: Lymphoma of the
    kidney: A case of mistaken identity. *Infections in Urology*
    14:46-48, 2001.

83. Little RF, Gutierrez M, Jaffe E, Pau A, Horne M, Masur H, Wilson W:
    HIV-associated non-Hodgkin lymphoma: incidence, presentation, and
    prognosis. *JAMA* 285:1880-1885, 2001.

84. Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M,
    Wilson WH, Jaffe ES: Cutaneous lymphomatoid granulomatosis:
    Correlation of clinical and biological features. *Am J Surg Pathol*
    25:1111-1120, 2001.

85. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson MA,
    FitzGerald DJ, Pastan I: High complete remission rate in
    chemotherapy-resistant classic or variant Hairy Cell Leukemia
    induced by the anti-CD22 recombinant immunotoxin BL22. *New Engl J
    Med* 345:241-247, 2001.

86. Pickarz RL, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM,
    Turner ML, Atlimus R, Bases SE: Inhibitor of histone deacetylation,
    depsipeptide (FR901228), in the treatment of peripheral and
    cutaneous T-cell lymphoma. *Blood* 98:2865-2868, 2001.

87. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang
    L, Pickeral O, Powell J, Botstein D, Byrd JC, Grever MR, Chiorazzi
    N, Wilson WH, Kipps TJ, Brown PO, Staudt LM: Relation of gene
    expression phenotype to immunoglobulin mutation genotype in Chronic
    Lymphocytic Leukemia. *J Exp Med* 194:1639-1647, 2001.

88. Gill R, Van Waes C, Kass E, Wilson W: Lymphomas of the head and
    neck; In Otolaryngology and Facial Plastic Surgery. *Emedicine*
    2:10-15, 2001.

89. Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA,
    Grossbard ML: Role of rituximab and chemotherapy in aggressive
    B-cell lymphomas: A preliminary report of dose-adjusted EPOCH-R.
    *Semin Oncol* 29:41-47, 2002.

90. Wilson WH, Grossbard ML, Pittaluga, S, Cole D, Pearson D, Drbohlav
    N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt
    L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R,
    Balis F: Dose-adjusted EPOCH chemotherapy in untreated large B-cell
    lymphomas: A novel pharmacodynamic approach with high efficacy.
    *Blood* 99:2685-2693, 2002.

91. Rosenwald A, Wright G, Campo E, Chan WC, Fisher RI, Gascoyne R,
    Muller-Hermelink HK, Smeland EB, Staudt LS, for the
    Lymphoma/Leukemia Molecular Profiling Project. Author list by
    Lymphoma/Leukemia Molecular Profiling Project (LLMPP) Consortium
    Center: Rosenwald A, Wright G, Giltnane JM, Hurt EM, Zhao H, Averett
    L, Yang L, Powell J, Duffey PL. Longo DL, Wilson WH, Jaffe E, Simon
    R, Klausner RD, Staudt LM et al. Molecular Diagnosis and Clinical
    Outcome Prediction in Diffuse Large B-cell Lymphoma. *N Engl J Med*
    346:1937-1947, 2002.

92. Gutierrez ME, Wilson WH: Salvage chemotherapy of non-Hodgkin's
    lymphomas. In Malignant Lymphoma. B.C. Decker, Inc, London. Salvage
    Chemotherapy of Non-Hodgkin's Lymphoma. P 289-300.

93. Hegde U, Wilson WH, White T, Cheson BD: Rituximab Treatment of
    Refractory Fludarabine-associated Immune Thrombocytopenia in Chronic
    Lymphocytic Leukemia. *Blood* 100:2260, 2002.

94. Staudt L, Wilson WH: Focus on Lymphoma. *Cancer Cell* 2:363, 2002.

95. Bryant-Greenwood PK, Sorbara L, Filie AC, Little R, Yarchoan R,
    Wilson W, Raffeld M, Abati A: Infection of mesothelial cells with
    human herpes virus 8 in human immunodeficiency virus-infected
    patients with Kaposi's Sarcoma, Castleman's Disease and recurrent
    pleural effusions. *Mod Path* 16:145, 2003.

96. Little RF, Pittaluga S, Drbohlav N, Steinberg SM, Kavlick MF,
    Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G,
    Yarchoan R, and Wilson WH: Highly effective treatment of acquired
    immunodeficiency syndrome related lymphoma with dose adjusted EPOCH:
    Impact of anti-retroviral therapy suspension and tumor biology.
    *Blood* 101:4653, 2003.

97. Leonard GD, Hege U, Butman JH, Jaffe ES, Wilson WH: Extraocular
    muscle palsies in subcutaneous panniculitis-like T-cell lymphoma. *J
    Clin Oncol* 21:2993, 2003.

98. Wiestner A, Rosenwald A, Barry T, Wright G, Davis RE, Henrickson SE,
    Zhao H, Ibbotson RE, Orchard JA, Davis Z, Steterler-Stevenson M,
    Raffeld M, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM:
    ZAP-70 expression identifies a chronic lymphocytic leukemia subtype
    with unmutated immunoglobulin genes, inferior clinical outcome and
    distinct gene expression profile. *Blood* 101:4944, 2003.

99. Little RF, Wilson WH: Update on the pathogenesis, diagnosis and
    therapy of AIDS-related lymphoma. *Curr Infect Dis Rep* 5:176, 2003.

100. Rosenwald A, Wright G, Weistner A, Chan WC, Connors JM, Campo E,
     Fisher RI, Gascoyne R, Muller-Hermelink HK, Smeland EB, Chiorazzi
     M, Giltnane JM, Hurt EM, Zhao H, Averett L. Henrickson S, Yang L,
     Powell J, Wilson WH, Jaffe E, Simon R, Klausner RD, Montserrat E,
     López-Guillermo A, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ,
     Lynch JC, Vose J, Armitage JO, Grogan TM, Miller TP, LeBlanc M, Ott
     G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The
     Proliferation Gene Expression Signature is a Quantitative
     Integrator of Oncogenic Events that Predicts Survival in Mantle
     Cell Lymphoma. *Cancer Cell* 3:185, 2003.

101. Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K,
     Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler
     DH. Establishment of early donor engraftment after
     reduced-intensity allogeneic hematopoietic stem cell
     transplantation to potentiate the graft-versus-lymphoma effect
     against refractory lymphomas. *BBMT* 9:162, 2003.

102. Nguyen JD, Carrasquillo JA, Little RF, Ryan QC, Wilson W, Chen CC.
     Fluoro-deoxyglucose positron emission tomography in the presence of
     cardiac metastases. *Clin Nucl Med* 28:979, 2003.

103. Wilson WH: Commentary: DNA Microarrays in Lymphoid Malignancies.
     *Oncology* 17:1759, 2003.

104. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R, Chan
     WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose
     J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E,
     Montserrat E, López-Guillermo A, Ott G, Muller-Hermelink HK,
     Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M,
     Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon
     R, Klausner RD, Staudt LM. Molecular diagnosis of primary
     mediastinal B cell lymphoma identifies a clinically favorable
     subgroup of diffuse large B cell lymphoma related to Hodgkin
     lymphoma*. J Exp Med* 198:851, 2003.

105. Murdock J, Jaffe ES, Wilson WH, McManus DT et al: Aggressive
     natural killer cell leukemia/lymphoma: Care report, use of
     telesynergy and review of the literature. *Leukemia and Lymphoma*
     45:1269, 2004.

106. Hegde U, Wilson WH: New Treatment Strategies in Chronic Lymphocytic
     Leukemia.

> In Treatment of Chronic Lymphocytic Leukemias. In Chronic Lymphocytic
> Leukemia: Pages 315-328. Editor Faguet G.B, Human Press, Totowa, New
> Jersey. 2004.

107. Jaffe ES and Wilson WH: Grey zone, synchronous and metachronous
     lymphomas: Diseases at the interface of Hodgkin and non-Hodgkin
     lymphomas. Non-Hodgkin's Lymphomas. Eds. Mauch PM, Armitage JO,
     Coiffier B, Dalla-Favera R and Harris NL. Lippiincott Williams and
     Wilkins Publisher, Philadelphia, 2004.

108. Dunleavy K, Staudt LM, Wilson WH: Clinical Applications of
     Molecular Profiling in Lymphomas. Progress in Oncology. Eds. Devita
     VT, Hellamn S and Rosenberg SZ. Jones and Bartlett Publishers,
     Sudbury, Massachusetts, 2004.

109. Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES,
     Drbohlav N, Gutierrez M, Waldmann TA, Wilson WH: Serum soluble
     interleukin-2 receptor levels are elevated in patients with
     anaplastic large cell lymphoma. *Blood* 104:3355, 2004.

110. Rosenwald A, Chuang EY, Davis RE, Wiestner A. Alizadeh AA, Botstein
     D, Brown PO, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt
     LM: Fludarabine Treatment of Chronic Lymphocytic Leukemia Patients
     Induces a p53-Dependent Gene Expression Response. *Blood* 104:1428,
     2004.

111. Mattu R, Sorbara1 L, Filie A, Little R, Wilson W, Raffeld M, Abati
     A: Utilization of Polymerase Chain Reaction on Archival Cytologic
     Material: a Comparison with Fresh Material with Special Emphasis on
     CSFs. *Mod Path* 17:1295, 2004.

112. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher
     RI, Braziel RM, Grogan TM. Miller TP, LeBlanc M, Greiner TC,
     Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy
     S, Holte H, Delabie J, Connors JM, Lansdorp P, Ouyang Q, Lister TA,
     Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E,
     Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao
     H, Goldschmidt N, Chiorazzi M, Staudt LM: Survival Following
     Diagnosis of Follicular Lymphoma is Predicted by Molecular Features
     of Non-malignant Tumor-infiltrating Immune Cells. *New Eng J Med*
     351:2159, 2004.

113. Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland
     SM, Wilson WH: Non-Hodgkin's lymphoma in Job's syndrome: A case
     report and literature review. *Leukemia and Lymphoma* 45:2521,
     2004.

114. Little R, Gutierrez M, Wilson WH: Non-Hodgkin's Lymphoma. Clinical
     Hematology, Elsevier, 2004.

115. Wilson W, Supko J: Pharmacology and Toxicity of Anti-Neoplastic
     Agents. Hematology, eds. Williams, 2004.

116. Wilson WH. Principals of Treatment in "The Lymphomas". 2^nd^
     Edition. Editors: Canellos G, Lister TA, and Young B. Saunders.
     2004.

117. Chabner BA, Wilson W, Supko J: Pharmacology and Toxicity of
     Anti-Neoplastic Agents. Goodman and Gilman, 2004.

118. Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan
     CD.  Hemophagocytosis and coagulopathy associated with cutaneous
     gamma-delta T-cell lymphoma. *Transfusion* 44:1679, 2004.

119. Grube M, Rezvani M, Wiestner A, Fujiwara H, Sconocchia G,
     Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA.
     Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived
     from Normal B-Cell Differentiation Antigens in Healthy Individuals
     and Patients with B-Cell Malignancies. *Clin Ca Res* 10:1047, 2004.

120. Lunning MA, Zenger VE, Dreyfuss R, Stetler-Stevenson M, Rick ME,
     White TA, Wilson WH, Marti GE: Albumin enhanced morphometric image
     analysis in CLL. *Cytometry B Clin Cytom* 57:7, 2004.

121. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM,
     Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson MA, Wilson WH:
     High incidence of occult leptomeningeal disease detected by flow
     cytometry in newly diagnosed aggressive B-cell lymphomas at risk of
     central nervous system involvement: The role of flow cytometry
     versus cytology. *Blood* 105:496, 2005.

122. Gutierrez M, Little R, Wilson WH: Non-Hodgkin's Lymphoma. *Bethesda
     Handbook of Clinical Oncology.* Second edition. Editors Abraham J,
     Allegra CJ and Gulley J. Lippincott Williams and Wilkins,
     28:357-375, 2005.

123. Abraham J, Wilson W, Jaffe E: Hodgkin's Lymphoma. *Bethesda
     Handbook of Clinical Hematology*. Editors Rodgers GP and Young NS.
     Lippincott Williams and Wilkins, 15:186-198, 2005.

124. Little RF, Gutierrez M, Wilson WH. Non-Hodgkin's Lymphoma.
     *Bethesda Handbook of Clinical Hematology*. Editors Rodgers GP and
     Young NS. Lippincott Williams and Wilkins, 16:199-220, 2005.

125. Patsalides A, Hegde U, Butman JA, Jaffe E, NJ Patronas NJ, Wilson
     WH: Central nervous system radiological abnormalities in
     lymphomatoid granulomatosis. *Radiology* 237:265-273, 2005.

126. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White
     T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH. B-cell Recovery
     Following Rituximab-Based Therapy Is Associated with Perturbations
     in Stromal Derived Factor-1 and Granulocyte Homeostasis. *Blood*
     106:795, 2005.

127. Dunleavy K, Wilson WH: Lymphomas in *American College of Physicians
     Medicine*. Section 12, 2005.

128. Neelapu SS, Kwak LW, Kobrin CB, Janik J, Dunleavy K, White T,
     Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg S,
     Gress R, Hakim F, Wilson WH: Vaccine-induced tumor-specific
     immunity despite severe B-cell depletion in mantle cell lymphoma.
     *Nat Med* 11:986-991, 2005.

129. Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W,
     Stetler-Stevenson MA. Flow cytometric immunophenotypic profiles of
     mature gamma delta T-cell malignancies involving peripheral blood
     and bone marrow. *Cytometry B Clin Cytom*. 67:6-12, 2005.

130. Kreitman RJ, Squires DR, Stetler-Stevenson AM, Noel P, FitzGerald
     DJP, Wilson WH and Pastan I. Phase I Trial of Recombinant
     Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients with B-cell
     Malignancies. *J Clin Oncol* 23:6719-6729, 2005.

131. Fu K, Weisenburger DD, Greiner TC, Dave S, Chiorazzi M, Wright G,
     Gesk S, Siebert R, De Jong D, Jaffe ES, Delabie J, Ott G, Wilson W,
     Braziel RM, Dave BJ, Sanger WG, Smith LM, Müller-Hermelink HK,
     Campo E, Gascoyne RD, Rosenwald A, Staudt LM, and Chan WC: Cyclin
     D1-Negative Mantle Cell Lymphoma: A Gene Expression Profiling,
     Genetic and Clinicopathological Study. *Blood* 106:4315, 2005.

132. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C,
     Kasten-Sportes C, Gress RE, Bishop MR: Efficacy of
     Reduced-Intensity Allogeneic Stem Cell Transplantation in
     Chemotherapy-Refractory Non-Hodgkin's Lymphoma. *Biol Blood Marrow
     Transplant* 11:593, 2005.

133. Wilson WH: R-CHOP Strikes Again with Survival Benefit in Follicular
     Lymphoma: Where do we go from here? *Blood* 106: 3678-3679, 2005.

134. Wilson WH: Long Term Results of the R-CHOP Study in Elderly
     Patients with DLBCL. *Am J Oncology Rev* 4:650-650, 2005.

135. Aurran-Schleinitz T, Telford W, Perfetto S, Caporaso N, Wilson W,
     Stetler-Stevenson MA, Zenger VE, Abbasi F, Marti GE. Identification
     of a new monoclonal B-cell subset in unaffected first-degree
     relatives in familial chronic lymphocytic leukemia. *Leukemia*
     19:2339-2341, 2005.

136. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C,
     Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC,
     Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM,
     Braziel R, Fisher RI, Smeland EB, Kvaloy S, Delabie J, Simon R,
     Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK,
     Staudt LM, Campo E, Rosenwald A: Diffuse Large B Cell Lymphoma
     Subgroups Have Distinct Genetic Profiles that Influence Tumor
     Biology and Improve Gene Expression-Based Survival Prediction.
     *Blood* 106:3183, 2005.

137. Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P,
     Rosenberg J, Wilson WH, Robinson MR: The Pharmacokinetics of
     Rituximab following an Intravitreal Injection. *Exp. Eye Res.*
     82:760, 2006.

138. Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ: Radiofrequency
     Ablation of Lymphoma. *Blood* 107:1624, 2006.

139. Chabner BA, Amrein PC, Druker B, Michaelson MD, Mitsiades CS, Goss
     PE, Ryan DP, Ramachandra S, Richardson PG, Supko JG and Wilson WH:
     Chemotherapy of Neoplastic Diseases: Antineoplastic Agents in
     *Goodman and Gilman's The Pharmacological Basis of Therapeutics.*
     Eleventh edition. Editors Brunton LL, Lazo JS and Parker.
     McGraw-Hill, New York. 51:1315-1404, 2006.

140. Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F,
     Tretler J, Fleisher T, Puck JM, Wilson W, Jaffe ES, Avila N, Chen
     CC, Straus SE. Fluorodeoxyglucose Positron Emission Tomography (FDG
     PET) for Monitoring Lymphadenopathy in the Autoimmune
     Lymphoproliferative Syndrome (ALPS*). Amer J Heme* 81:81, 2006.

141. Schinstine M, Filie AC, Wilson W, Stetler-Stevenson MA, and Abati
     A: Detection of Malignant Hematopoietic Cells in Cerebral Spinal
     Fluid Previously Diagnosed as Atypical or Suspicious. *Cytology*
     (In Press).

142. Janik J, Jaffe ES and Wilson WH: Cutaneous T-cell Lymphomas.
     *Lancet Oncology* (submitted).

143. Dunleavy K, Wilson WH: The Case for Rituximab in AIDS-Related
     Lymphoma. *Blood* 107:3014-3015, 2006.

144. Dave SS, Fu K, Wright GE, Lam LT, Greiner TC, Weisenburger DD,
     Kluin P, Boerma EJ, Rosenwald A, Ott G, Muller-Hermelink HK,
     Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E,
     Jaffe ES, Vose J, Armitage JO, Connors JM, Smeland EB, Kvaloy S,
     Holte H, Fisher RI, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang
     L, Powell J, Simon R, Chan WC, Staudt LM for the Leukemia Lymphoma
     Molecular Profiling Project: Gene Expression Distinguishes Burkitt
     Lymphoma From Other Aggressive Lymphomas and Identifies Patients
     who are Curable with Intensified Chemotherapeutic Regimens. *N Engl
     J Med* (In Press).

145. Kreitman RJ, Wilson WH, Pastan I: Complete Remissions of Purine
     Analog-Resistant Hairy Cell Leukemia Induced by the Anti-CD22
     Recombinant Immunotoxin BL22. Trends in Diphtheria Research, Nova
     Science Publishers, Inc, Hauppauge, New York. (In Press).

146. Dunleavy K, Wilson WH: HIV-Associated Lymphoid Neoplasms. The
     Lymphoid Neoplasms, 3^rd^ Edition. Editor Ian Magrath. Hodder
     Arnold, London. (In Press).

147. Bernstein WB, Little RF, Wilson WH, Yarchoan R: AIDS-Related
     Malignancies in the HAART Era. *Int. J. Heme* (Submitted).

148. Wayne A, Wilson WH: Burkitt and Lymphoblastic Lymphoma. Lymphoma:
     Diagnosis and Treatment. Editors Marcus R, Sweetenham J and
     Williams M. Cambridge University Press, Cambridge. (In Press).

149. Dunleavy K, Wilson WH: Primary Intraocular Lymphoma: Current and
     Future Perspectives. *Leukemia and Lymphoma* (In Press).

150. Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M.
     International Central Nervous System & Ocular Lymphoma Workshop:
     Recommendations for the future. *Eye* (In Press).

151. Wilson WH. Drug Resistance in Diffuse Large B-cell Lymphoma. *Semin
     Heme* (In Press).

> **Invited Lectures and Meetings**

**(Selected From 2000-Present)**

1.  Recent Advances in Lymphoma. Legislative Update, Lymphoma Research
    Foundation of America, 2000.

2.  Chemotherapy sensitization by rituximab. Second annual opinion
    leader roundtable on: Recent advances and future directions with
    rituximab, 2000.

3.  Development of EPOCH chemotherapy. Department of Hematology/Oncology
    Grande Rounds, University of Maryland, 2000.

4.  Recent Advances in Lymphoma. Legislative Update, Lymphoma Research
    Foundation of America, 2000.

5.  Clinical Trials in CLL. CLL Research Cooperative. San Diego,
    California, 2000.

6.  Innovative Treatments of Aggressive Lymphomas. Department of
    Oncology, Washington Hospital Center, Washington, DC, 2000.

7.  Lymphoma and Sjogren's Syndrome. Sjogren's Syndrome Conference.
    NIDCR, National Institutes of Health, Bethesda, Maryland, 2000.

8.  Infusional Chemotherapy. Lymphoma and Myeloma 2000 at the Turn of
    the Century, Cornell University, New York, New York, 2000.

9.  Treatment of AIDS-Related Lymphomas. Grand Rounds, Clinical Center,
    NIH, Bethesda, Maryland, 2000.

10. Advances in the Treatment of HIV-Associated Lymphomas. National
    Cancer Advisory Board, National Cancer Institute, NIH, Bethesda,
    Maryland, 2000.

11. EPOCH-Rituximab in untreated patients with high risk large B-cell
    lymphomas. Third annual opinion leader roundtable on recent advances
    and future directions with rituximab, 2001.

12. Advances in the treatment of non-Hodgkin's lymphomas. Symposium on
    cancer treatment, City Hospital, Martinsburg, West Virginia, 2001.

13. Recent Advances in Lymphoma. Legislative Update, Lymphoma Research
    Foundation of America, 2001.

14. Advances in the treatment of aggressive lymphomas with rituximab.
    International Symposium on Monoclonal Antibodies, Banff, Canada,
    2001.

15. New Treatments of Lymphomas. B-cell Malignancies and chronic
    leukemias: Advances in biology and therapy. Fox Chase Cancer Center,
    Philadelphia, PA, 2001.

16. Clinical Treatment of Lymphomas. Session Moderator, Proc Am Soc
    Heme, 2001.

17. Leukemia, Lymphoma, Myeloma Progress Review Group, Session Moderator
    and Speaker, Proc Am Soc Heme, 2001.

18. Development of Taxol Treatment. NIH Research Festival, 2002.

19. New Treatments of Large B-cell Lymphomas. Holy Cross Hospital, Ft
    Lauderdale, Florida, 2002.

20. 1^st^ International Workshop on non-Hodgkin's Lymphoma, Scientific
    Advisory Committee, Chantilly, France, 2002.

21. Conference on Advances in Lymphomas: Rituximab Treatment of
    Aggressive Lymphomas. Miami, Florida, 2002.

22. Lymphomatoid Granulomatosis: Pathogenesis, Pathobiology and
    Treatment. Organizer, Airlie Conference Center, Virginia, 2002.

23. Clinical Drug Development. Innovations in Lymphoma Treatment, New
    York, New York, 2002.

24. GELA: Novel Treatments of Large B-cell Lymphomas, Paris, France,
    2003.

25. 7^th^ Annual Winter Oncology Conference: Novel Approaches to
    Management of Aggressive NHL. Whistler, Canada, 2003.

26. Grand Rounds, University of Vermont, Burlington, Vermont, 2003.

27. Grand Rounds, George Washington University, Washington, DC, 2003.

28. Grand Rounds and Visiting Professor, St. Bartholomew's Hospital:
    Treatment of AIDS Related Lymphomas. London, UK, 2003.

29. Third Congress on Monoclonal Antibodies in Cancer: Integrating
    antibodies in aggressive B-cell Lymphomas, Quebec, Canada, 2003.

30. Second International Ultmann Symposium on the Diagnosis and
    Management of Lymphoma: The Role of Dose Intensity in Large Cell
    Lymphoma: Second International, University of Chicago, Chicago, Ill,
    2003.

31. 2nd International Workshop on non-Hodgkin's Lymphoma, Scientific
    Advisory Committee: Idiotype Vaccine in Mantle Cell Lymphoma,
    Niagra, Canada, 2003.

32. Novel Technologies in Oncology: Key note speaker: Rationale
    Treatment Approaches in Aggressive Lymphomas: Role of microarray and
    pharmacodynamics. University of West Virginia, Morgantown, West
    Virginia, 2003.

33. Cancer Therapy Evaluation Program Phase I Conference: Phase I Study
    of UCN-01 and Fludarabine in Lymphomas, Bethesda, MD, 2003.

34. 1^st^ Combined Lymphoma and Transplant Conference: Advances in the
    Treatment of Aggressive Lymphoma, M.D. Anderson, Houston, Texas,
    2004.

35. Lymphoma Conference: Treatment of Mantle Cell Lymphoma. University
    of California, Los Angeles, Los Angeles, CA, 2004.

36. Southern California Lymphoma Group. Treatment of Diffuse Large
    B-cell Lymphoma. Los Angeles, CA, 2004.

37. Molecular Oncology Seminar Series. Treatment and Advances in AIDS
    Related Lymphoma. George Washington University, Washington, DC,
    2004.

38. Clinical Conference Series. Treatment of Diffuse Large B-cell
    Lymphoma. Loudoun Hospital Center, Loudoun, VA, 2004.

39. Advances in Hematologic Malignancies: Advances in the Treatment of
    Aggressive Lymphomas. Roswell Park Cancer Institute, Buffalo, NY,
    2004.

40. 8^th^ International Congress on Hematological Malignancies. Advances
    in the Treatment of Mantle Cell Lymphoma and Depsipeptide. Whistler,
    Canada, 2004.

41. Rituxan Investigator Meeting: Advances in the Treatment of Diffuse
    Large B-cell Lymphoma. Hollywood, Florida, 2004.

42. Enzon Pharmaceuticals Meeting. Treatment of Lymphomas. Orlando,
    Florida, 2004.

43. Washington Hospital Center. Advances in the Treatment of Aggressive
    Lymphomas. Washington, DC, 2004.

44. 3^rd^ International Workshop on Non-Hodgkin's Lymphoma: New
    Therapeutic Approaches to Aggressive Lymphoma, Stresa, Italy, 2004.

45. International Workshop on CNS and Ocular Lymphoma: Treatment of
    Systemic and Ocular Lymphoma, Bethesda, MD, 2004.

46. Controversies and Practical challenges in Hematological
    Malignancies: Testicular Cancer and Bortezomib in Non-Hodgkin's
    Lymphoma. Las Vegas, Nevada, 2004.

47. 2^nd^ Annual Lymphoproliferative Symposium; Orange County Cancer
    Education and Research Foundation: New Drugs and Treatments in
    Lymphoma and CLL. Newport Beach, CA, 2004.

48. Anticancer Drug Optimization: ASH Corporate Friday on New Strategies
    for Dose Intensification, San Diego, CA 2004.

49. Second Annual Indy Hematology Review: Advances in the Treatment of
    Indolent Lymphoma. Indianapolis, IN 2005.

50. Grand Rounds: Advances in the Treatment of Aggressive Lymphoma.
    Ireland Cancer Center, Case Western Reserve Medical School,
    Cleveland, OH 2005.

51. Lymphoma...the next questions: EPOCH-R combined with Vaccine Therapy
    for Mantle Cell non-Hodgkin's Lymphoma. Ft. Lauderdale, FL 2005.

52. New Treatments in Mantle Cell Lymphoma. 9^th^ International
    Conference on Malignant Lymphoma, Lugano, Switzerland, 2005.

53. Optimizing Treatment Strategies in Aggressive NHL. International
    Symposium on Lymphoma, Berlin, Germany, 2005.

54. Advances in the Treatment of Aggressive Lymphoma. Dana-Farber
    Science Writers Seminar, Dana-Farber Cancer Center, Boston,
    Massachusetts, 2005.

55. Targeted Treatment of Lymphoma. Think Tank on Molecular Targets in
    Lymphoid Malignancies. Natcher Conference Center, NIH, Bethesda, MD
    2005.

56. Treatment of Diffuse Large B-cell Lymphoma. Grand Rounds, University
    of Wisconsin, Madison, Wisconsin, 2005.

57. Unusual T-cell Lymphomas. Controversies in Hematological
    Malignancies. West Palm Beach, Florida, 2005.

58. Update on DA-EPOCH-R and CALGB Randomized Phase III Trial. 4^th^
    International Workshop on Non-Hodgkin's Lymphoma, Turnberry Isle
    Resort, Florida, 2005.

59. Frontline Therapy of Diffuse Large B-cell Lymphoma; Can We Implement
    an Emerging Molecular Prognostic Index. Hackensack University
    Symposium, Tuxedo Park, NY, 2005.

60. Diffuse Large B-cell Lymphoma: Treatment advances. Grand Rounds,
    University of Nebraska, Omaha, Nebraska, 2005.

61. Idiotype vaccine in mantle cell lymphomas. Corporate Friday
    Symposium at ASH on Clinical Advances in Idiotype Vaccine Therarpy
    for NHL. Atlanta, Georgia, 2005.

62. Educational Session on Aggressive Lymphomas, Chairman, American
    Society of Hematology, Atlanta, Georgia, 2005.

63. Grey zone lymphomas and lymphomatoid granulomatosis. First Annual
    Oncology World Congress, New York, New York, 2005.

64. Monoclonal Antibody Therapy in T-cell Lymphoma. 10^th^ International
    Congress on Hematological Malignancies, Whistler, Canada, 2006.

65. Unusual T-cell Lymphomas. 10^th^ International Congress on
    Hematological Malignancies, Whistler, Canada, 2006.

66. Treatment of Diffuse Large B-cell Lymphoma. Grand Round, University
    of Virginia, Charlottesville, Virginia, 2006.

67. Diagnosis of CNS Disease in Aggressive Lymphoma with Flow Cytometry.
    Symposium on Diagnosis and Treatment of CNS Lymphoma. European
    Hematology Association Meeting, Amsterdam, Netherland, 2006.

68. Flow Cytometry of the CSF. Symposium on the Diagnosis of CSF
    Lymphoma. European Hematology Association Meeting, Amsterdam,
    Netherland, 2006.

69. Rituximab: An ideal monoclonal antibody based therapeutic? 6^th^
    International Congress on Monoclonal Antibodies in Cancer.
    Washington, DC, 2006.